BrainsWay

BrainsWay’s Deep TMS platform has received FDA clearance for major depressive disorder—including treatment-resistant cases—anxious depression symptoms in MDD patients, OCD (first de novo noninvasive device cleared for this indication), late-life depression in elderly patients aged 68–86 years old (first TMS device with this indication), and short-term smoking cessation. Clinical studies have demonstrated significant response/remission rates; e.g., MDD patients over 68 treated with the H1 Coil showed up to 69% response rate on HDRS-21 scale. Over 60 clinical trials have been conducted globally supporting efficacy and safety.